Guidelines for Biologicals in Psoriasis: American [AAD] and British Association of Dermatology [BAD] скачать в хорошем качестве

Guidelines for Biologicals in Psoriasis: American [AAD] and British Association of Dermatology [BAD]

Hi. With this video, we will discuss the American Academy of Dermatology and British Academy of Dermatology Guidelines for the treatment of psoriasis using FDA-approved biologicals. This video is directed towards dermatologists and is not at all advisory for non-medical personnel. Beginning - 00:00 Disclaimer for Guidelines - 04:33 Grade Of Recommendation [AAD] - 06:33 Adalimumab - 08:48 Infliximab - 12:08 Etanercept - 15:07 Certolizumab Pegol - 17:59 General Comments about TNFIs - 19:17 Summary of recommendations for TNFIs - 26:55 Ustekinumab - 28:57 Secukinumab - 33:00 Summary of recommendations for Ustekinumab and Secukinumab - 35:25 Role of Dermatologists - 36:06 General considerations for biologicals - 37:50 BAD Guidelines - 42:48 Using Biologicals - 45:13 Criteria for Biologicals - 47:03 Prescribing and Reviewing Biologicals - 48:35 Choice of Biologicals - 51:14 Dose escalation / Interval reduction - 54:02 Pediatric Considerations - 55:10 Pregnancy and Contraception - 56:16 Further reading - 58:19 End - 59:34 AAD Guidelines for biologicals in psoriasis: https://www.jaad.org/action/showPdf?p... BAD Guidelines for biologicals in psoriasis: Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628-637. doi:10.1111/bjd.19039 Indian Scenario: Rajagopalan M, Mital A. Biologics use in Indian psoriasis patients. Indian Dermatol Online J. 2016;7(6):489-497. doi:10.4103/2229-5178.193915